245 related articles for article (PubMed ID: 12584032)
21. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.
Taga M; Uemura T; Minaguchi H
J Endocrinol Invest; 1998 Mar; 21(3):154-9. PubMed ID: 9591210
[TBL] [Abstract][Full Text] [Related]
22. Serum leptin as a determinant of bone resorption in healthy postmenopausal women.
Roux C; Arabi A; Porcher R; Garnero P
Bone; 2003 Nov; 33(5):847-52. PubMed ID: 14623061
[TBL] [Abstract][Full Text] [Related]
23. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
24. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
[TBL] [Abstract][Full Text] [Related]
25. Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption.
Aonuma H; Miyakoshi N; Hongo M; Kasukawa Y; Shimada Y
Tohoku J Exp Med; 2009 Jul; 218(3):201-5. PubMed ID: 19561390
[TBL] [Abstract][Full Text] [Related]
26. Urinary alpha and beta C-telopeptides of collagen I: clinical implications in bone remodeling in patients with anorexia nervosa.
de la Piedra C; Calero JA; Traba ML; Asensio MD; Argente J; Muñoz MT
Osteoporos Int; 1999; 10(6):480-6. PubMed ID: 10663349
[TBL] [Abstract][Full Text] [Related]
27. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
[TBL] [Abstract][Full Text] [Related]
28. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men.
Fall PM; Kennedy D; Smith JA; Seibel MJ; Raisz LG
Osteoporos Int; 2000; 11(6):481-5. PubMed ID: 10982162
[TBL] [Abstract][Full Text] [Related]
29. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
[TBL] [Abstract][Full Text] [Related]
30. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
31. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
[TBL] [Abstract][Full Text] [Related]
32. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
33. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.
Lehmann HJ; Mouritzen U; Christgau S; Cloos PA; Christiansen C
Ann Rheum Dis; 2002 Jun; 61(6):530-3. PubMed ID: 12006327
[TBL] [Abstract][Full Text] [Related]
34. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
35. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
36. Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age- and sex-related changes and reference limits.
Sone T; Miyake M; Takeda N; Fukunaga M
Bone; 1995 Oct; 17(4):335-9. PubMed ID: 8573404
[TBL] [Abstract][Full Text] [Related]
37. Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratory.
Chailurkit LO; Ongphiphadhanakul B; Piaseu N; Saetung S; Rajatanavin R
Clin Chem; 2001 Jun; 47(6):1083-8. PubMed ID: 11375295
[TBL] [Abstract][Full Text] [Related]
38. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
Hannon R; Blumsohn A; Naylor K; Eastell R
J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
[TBL] [Abstract][Full Text] [Related]
39. Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover.
Garnero P; Stevens RE; Ayres SA; Phelps KV
J Clin Pharmacol; 2002 Mar; 42(3):290-6. PubMed ID: 11865965
[TBL] [Abstract][Full Text] [Related]
40. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
